About The Study: The data from this study support the potential benefit of oral semaglutide in reducing heart failure events in people with type 2 diabetes and heart failure.
Corresponding Author: To contact the corresponding author, Rodica Pop-Busui, MD, PhD, email busui@ohsu.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.7774)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.7774?guestAccessKey=237e7119-d498-4abf-93ce-97f2b8693e7c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020226
Journal
JAMA Internal Medicine